Bright Minds Biosciences (DRUG) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 41.4% versus a loss of 12.0%. Over five years, DRUG leads with a +45.5% price change compared with -31.7% for OVID. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $480.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | OVID |
|---|---|---|
| Share price | $54.05 | $2.46 |
| Market cap | $533.15M | $480.43M |
| 1-day change | +3.94% | +5.13% |
| YTD return | -30.74% | +50.92% |
| 1-year return | -11.99% | +41.38% |
| 5-year return | +45.49% | -31.67% |
| EPS (TTM) | $-2.13 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $3.11 |
| 52-week low | $47.23 | $1.18 |
| Distance from 52-week high | -56.32% | -20.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +181.17% | +144.72% |
| Average volume | 155.37K | 1.57M |
| Shares outstanding | 9.86M | 195.30M |
| Employees | 26 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed DRUG by 53.4 percentage points over the past year.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
DRUG vs OVID FAQ
Which is bigger, Bright Minds Biosciences or Ovid Therapeutics?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $480.43M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, DRUG or OVID?
OVID returned +41.38% over the past 12 months, compared with -11.99% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.